A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”
Moderna reports $1.2bn net loss in Q1 2024
Moderna attributed the decline in revenues to the reduced sales of its Covid-19 vaccine. Credit: Tada Images / Shutterstock.com. Moderna experienced a substantial financial shift